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Abstract
Background: Medication overuse headache (MOH) is a common and debilitating disorder characterized by
generation, perpetuation, and persistence of intense chronic migraine, caused by overuse of analgesics, triptans, or
other acute headache compounds. It has been suggested that MOH could share some pathogenetic mechanisms
with other kinds of drug addiction. In this regard, histone deacetylases 3 (HDAC3) seems to have a role in the
memory processes involved in extinction of drug-seeking behavior in animal models. HDAC3 is inhibited by sodium
valproate, a drug with proven efficacy in MOH. Recent evidence suggests an involvement of genetic factors in
predisposition to medication overuse.
Results: In this association study, we sequenced all exons, intron/exon junctions, and 3′-5′UTR regions of HDAC3 in
23 MOH patients to investigate its role in medication overuse. Associations between genotypes with continuous
and dichotomous clinical characteristics were tested by multivariate analysis and Fisher’s exact test, respectively.
Sequencing of HDAC3 revealed six single-nucleotide polymorphisms. The G allele of rs2530223 was significantly
associated with the number of acute medications/month used and with the number of days/month in which
medications were used (p = 0.006 and p = 0.007, respectively), but neither with headache frequency or intensity.
None of the single-nucleotide polymorphisms (SNPs) was associated with clinical characteristics or response to
sodium valproate.
Conclusions: HDAC3 could be implicated in excessive medication consumption in MOH patients. Our preliminary
findings provide support for the need of further investigation on larger independent samples to confirm and
extend the role of HDAC3 in medication overuse headache.
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Background
Medication overuse headache (MOH) is a common and
debilitating disorder characterized by generation, per-
petuation, and persistence of intense chronic migraine,
caused by overuse of analgesics, triptans, or other acute
headache compounds [1]. Epidemiological studies show
that MOH has become the third most frequent type of
headache, with a prevalence of 1–2 % of the general
population [2].
An increased risk of developing MOH has been shown
in subjects with a family history of medication, drug, or
alcohol abuse, suggesting a genetic predisposition to
medication overuse [3]. Moreover, genetic variants have
been suggested to have a role in migraine transformation
into MOH [4], success of detoxification therapy [5], and
relapse during the first year of follow-up [6].
The use of acute medication with psychotropic effects
(barbiturates and opioids) has been associated with in-
creased risk of migraine chronification [7]. MOH
* Correspondence: gpatrinos@upatras.gr; delzompo@unica.it
4Department of Pharmacy, University of Patras, School of Health Sciences,
Patras, Greece
1Section of Neurosciences and Clinical Pharmacology, Department of
Biomedical Sciences, University of Cagliari, SP8 Km. 0,700, 09042 Monserrato
(CA), Italy
Full list of author information is available at the end of the article
© 2015 Pisanu et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pisanu et al. Human Genomics  (2015) 9:30 
DOI 10.1186/s40246-015-0051-1
patients show symptoms of withdrawal [3], a high rate of
relapses [8], and decision-making deficits [9].
A neuroimaging study with 18F-fluorodeoxyglucose
positron-emission tomography in MOH patients showed
that a number of dysmetabolic brain areas involved in
pain-processing recovered after withdrawal of medica-
tion, while long-lasting dysfunction was observed in
orbitofrontal cortex [10], an area suggested to be in-
volved in drug dependence and addiction [11]. A recent
study has also identified persistent dysfunctions in the
mesocorticolimbic dopamine circuit in MOH patients
[12]. On the basis of this evidence, it has been specu-
lated that MOH shares some pathogenetic mechanisms
with other kinds of drug addiction [13, 14].
Histone deacetylases 3 (HDAC3) is a protein expressed
in almost all tissues, including brain [15], responsible for
the deacetylation of lysine residues of the core histones.
Among other functions, HDAC3 has been shown to be in-
volved in negative regulation of long-term memory forma-
tion [16]. It has been suggested that molecular mechanisms
underlying drug overuse are similar to those regulating
long-term associative memory [17]. HDAC3 inhibition has
been found to increase the memory processes involved in
the extinction of drug-seeking behavior in animal models
[18]. Moreover, HDAC3 expression has recently been
found to be increased in rat dorsal striatal neurons which
were activated during drug-seeking tests after prolonged
methamphetamine withdrawal compared to nonactivated
Fos-negative neurons [19].
Interestingly, this enzyme is inhibited by sodium val-
proate (VPA), an anticonvulsant and mood stabilizer ap-
proved by FDA for migraine prevention and shown to
be effective in the treatment of chronic daily headache
[20, 21]. Although VPA has been proven to be effica-
cious in the treatment of MOH with a history of mi-
graine without aura, the exact mechanism of action of
this drug in MOH is not known, and a large percentage
of treated patients do not respond [22].
In this study, we carried out an explorative investiga-
tion on the role of HDAC3 genetic variants in medica-
tion overuse and response to VPA treatment in a sample
of patients with MOH by sequencing of the functional
regions of the gene.
Results
Sequencing of the HDAC3 gene revealed five intronic
single-nucleotide polymorphisms (SNP) (rs1421896,
rs32954, rs2547547, rs149330805, and rs41290601) and
the synonym variant located in exon 3, rs2530223 (Fig. 1).
Percentages of successfully genotyped samples were 90 %
for rs1421896 and rs32954, and 100 % for all the
others SNPs. Genotyping was successful in all individuals.
Rs32954 had a minor allele frequency (MAF) lower than
0.01 and was excluded from the analyses. All SNPs were
already present in public databases (UCSC Genome Bio-
informatics; NCBI), and no new variants were identified in
our patients. All SNPs were in Hardy-Weinberg equilib-
rium (HWE) in our sample.
Multivariate analysis showed that rs2530223 was signifi-
cantly associated with the number of acute medications/
month used and days/month in which acute medications
were used (p = 0.02 and eta squared = 0.32 for both vari-
ables), but not with frequency or intensity of headache.
Specifically, GA and GG carriers showed a higher medica-
tion abuse compared to AA carriers. Since the means of
the associated variables were similar for GA and GG car-
riers, we hypothesized a recessive model for the effect of
the A allele on medication consumption, and we used this
model for subsequent analysis. When we grouped G allele
carriers, we found higher significance for number of
drugs/month abused and days/month of drug abuse for
both variables (p = 0.006, eta squared = 0.31; p = 0.007, eta
squared = 0.31, respectively; Table 1). G carriers were not
different from other subjects in regard to age or MOH
duration (Table 1). Although not significant, there was a
sex difference in our groups (in G carriers female
Fig. 1 Gene diagram of HDAC3 gene including SNPs identified in our sample. Abbreviations: SNP single-nucleotide polymorphism, MAminor allele,
MAF minor allele frequency. Allele frequencies for European population are reported accordingly to 1000 Genome Project [29]; data obtained through
VarioWatch [23]. The diagram was created with FancyGene [31]
Pisanu et al. Human Genomics  (2015) 9:30 Page 2 of 5
prevalence was 66 %, while it was 100 % among G noncar-
riers). For the numbers of drug/month abused, sex did
not give a significant contribution to the model when
tested as a covariate (p = 0.7). For the number of days/
month in which medications were used, sex was signifi-
cant as a covariate (p = 0.042), and the model including
sex and rs2530223 was significantly associated with
numbers of days/month of abuse (model: p = 0.003;
rs2530223: p = 0.022; sex: p = 0.042). When correcting
for headache frequency, the impact of rs2530223 on num-
ber of medications used and days of abuse remained sig-
nificant (p = 0.03 for both variables).
No HDAC3 SNP was associated with response to VPA
in our sample (data not shown). If used as a covariate in
the linear model including rs2530223 and numbers of
days/month of abuse, VPA response gave a nonsignificant
contribution (p = 0.8), while the contribution of the SNP
was still significant (p = 0.01). Thus, a different response to
VPA does not seem to be influencing the hypothesized as-
sociation between rs2530223 and medication consumption.
The analysis conducted with VarioWatch [23] showed
that rs2530223 was predicted to have a “high” functional
impact on HDAC3. VarioWatch assigns high functional
impact to variants falling into an exonic splicing en-
hancer (ESE) site and into the protein domain. F-SNP
database [24] showed that two out of four tools (ESR-
Search and PESX) predicted an effect of rs2530223
on splicing regulation.
Discussion
Our exploratory study investigated for the first time the
association between HDAC3 variants, medication over-
use, and other clinical variables in a sample of 23 MOH
patients. To this purpose, we sequenced exons, intron/
exon junctions, and 3′-5′UTR regions of the gene, and
we identified six SNPs, all of which resulted cataloged in
public databases. Our analyses showed a significant
association of the G allele of rs2530223 with higher medica-
tion consumption, but not with attack frequency or inten-
sity of headache. A recent study conducted in a small
sample of MOH patients showed that the amount of acute
medications taken for month was able to predict the prog-
nosis at a 1-year follow-up [25]. This observation was con-
firmed by a recent prospective study conducted in a larger
sample of MOH patients showing that overuse severity was
associated with negative outcome at a 3-year follow-up
[26]. Thus, understanding the basis of medication con-
sumption in MOH patients appears to be of great
relevance.
Our preliminary results suggest that rs2530223 could be
implicated in excessive medication consumption independ-
ently of the necessity of acute medication for pain relief.
The GG genotype of the same SNP has been associated
with cigarette smoking in a Korean population of schizo-
phrenia patients [p = 0.0054; odds ratio (95 % confidence
interval) = 4.33 (1.41-13.25)] [27]. Prevalence of smoking in
schizophrenia patients is three times higher compared to
general population, but carriers of the rs2530223 GG
genotype seem particularly predisposed to develop this
habit [27].
Although rs2530223 is a synonym variant, it could be
in strong linkage disequilibrium with rare functional var-
iants that our study was not powered enough to detect.
Moreover, VarioWatch predicted a high risk of func-
tional impact of this SNP on HDAC3. Our results sup-
port previous evidence suggesting an involvement of
genetic factors in predisposition to medication overuse
in MOH patients [28].
Allele frequencies of rs2530223 are population specific,
as the MAF in subjects with European, West African, or
East Asian ancestry is 0.4, 0.16, and 0.63, respectively,
accordingly to data from the 1000 Genome Project [29]
obtained through VarioWatch [23]. Further studies in
other ethnic groups are needed to assess the potential
Table 1 Association between clinical characteristics and genotypes of rs2530223
AA GA/GG Statistics p value Eta squared
Women/men 5/0 12/6 0.27
Age (years) 42.2 ± 10.9 43.1 ± 9.5 0.18 0.5
MOH duration 3.9 ± 3.8 5.4 ± 3.6 0.81 0.37
Number of headache days/month 18.6 ± 1.8 21.9 ± 4.1 3.04 0.09 0.12
Headache intensity 2.0 ± 0.7 2.2 ± 0.6 0.44 0.51 0.02
Number of drugs/month abused 14.2 ± 4.1 23.8 ± 6.7 9.47 0.006 0.30
Days/month of drug abuse 11.4 ± 2.6 19.0 ± 5.3 9.06 0.007 0.31
VPA responders/nonresponders 4/1 9/9 – 0.33
Continuous data are expressed in mean ± standard deviation; dichotomous data are expressed as frequencies
Headache intensity was measured with a 4-point scale with 0 = no pain, 1 = mild headache, 2 = moderate headache, 3 = severe headache. Headache attacks and
drugs used during the baseline period were collected using a headache diary. Additional information on how these variables were collected is available in Sarchielli et
al., 2014 [22]. Significant variables are indicated in bold
MOH medication overuse headache, VPA sodium valproate
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association of this SNP with medication consumption in
other populations.
In our sample, subjects with the rs2530223 AA geno-
type were characterized by a lower headache frequency
(p = 0.09). Thus, an alternative explanation for our re-
sults would be that subjects with this genotype show lower
medication consumption due to a lower number of days/
month with headache. After correcting for headache fre-
quency, the association between rs2530223 genotype and
medication consumption was still significant (p = 0.03).
While these results support our hypothesis that the SNP
could play a role in medication overuse in these patients,
the small sample size does not allow us to completely rule
out a major contribution of headache frequency in driving
significance. Findings from our study should be interpreted
in light of the pilot nature of this investigation. The small
sample size implemented could increase the risk for type 1
error and did not allow testing the effect of potentially rele-
vant modifying factors in our model. Another limitation of
the study is the small number of “AA” carriers in analysis
under the recessive model. Strengths of our study include
the prospective design and the choice to sequence HDAC3
instead of target genotyping.
In conclusion, our pilot study suggests the involve-
ment of HDAC3 in excessive medication consumption in
MOH patients. Our findings should be interpreted cau-
tiously due to the limited sample size and might repre-
sent a first step of future extensive research aiming to
clarify the role of HDAC3 in medication overuse.
Conclusions
HDAC3 could be implicated in excessive medication
consumption in MOH patients. These findings will serve
as proof of concept for further investigations that will
have to be performed on larger independent samples to
confirm and extend our preliminary findings.
Methods
Subjects
This is an ancillary study from the sodium valproate in the
treatment of medication overuse headache (SAMOHA)
multicenter, randomized, double-blind, placebo-controlled
study that enrolled 88 MOH patients for a 3-month treat-
ment period with VPA (800 mg/day) or placebo after a
6-day outpatient detoxification regimen, followed by a
3-month follow-up. The 3-month responder rate (the
proportion of patients achieving ≥50 % reduction in the
number of days with headache per month) was higher
in the VPA (45.0 %) than in the placebo arm (23.8 %)
with an absolute difference of about 20 % (p = 0.043).
VPA had safety and tolerability profiles comparable to
placebo [22]. Informed written consent for the molecu-
lar study was obtained from 23 subjects included in the
present work. All subjects undertook a venous blood
draw before starting detoxification regimen and VPA
therapy. The study was approved by the local Review
Board. Table 1 shows the characteristics of the sample.
Laboratory procedures
Genomic DNA was extracted from peripheral blood leu-
kocytes according to classical salting-out protocol. The
human HDAC3 gene is located on chromosome 5q31
and comprises 15 exons, for a length of 16 kb. The se-
quenced regions included all exons, intron/exon junc-
tions, and 3′-5′UTR regions.
Sequencing was carried out using the Big Dye Termin-
ator sequencing kit on an ABI-PRISM 3130XL Genetic
Analyzer (Applied Biosystems) according to the manu-
facturer’s protocol.
Statistical analysis
Sequences were analyzed with Sequence Scanner soft-
ware v1.0 and aligned to the reference sequence of
HDAC3 (UCSC Genome Bioinformatics) using BioEdit,
version 7.2.5. Deviation from the HWE was tested with
chi-square test. Polymorphisms with a MAF <0.01 were
excluded from the analyses. Association between geno-
types with continuous clinical characteristics and re-
sponse to VPA was tested by multivariate analysis and
Fisher’s exact test, respectively. Sex, headache frequency,
and response to VPA were tested in the model as covari-
ates. All the analyses were carried out with Haploview
version 4.2 [30] and SPSS version 20 (IBM Statistics). A
P value <0.05 was considered as statistically significant.
Functional impact of associated variants was calculated
with VarioWatch [23], a tool that assigns genomic vari-
ants a risk level on functional impact from “very low” to
“very high”. Analysis was conducted using standard pa-
rameters (selected region: 50 kbp upstream and 50 kbp
downstream of SNP position). Effect of associated vari-
ants on splicing regulation was assessed with F-SNP
[24], a database that predicts SNPs effect on splicing
regulation by integrating information of four different
tools: ESEfinder, RescueESE, ESRSearch, and PESX.
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